REGENXBIO Q3 revenue falls to $9.2 million; net loss narrows to $40.7 million
REGENXBIO reported third quarter 2026 results with revenue of $9.2 million, down from $29.7 million a year earlier, mainly because ZOLGENSMA royalties fell after U.S. patent expiry in January 2026. The net loss narrowed to $40.7 million, or $0.62 per share, from $61.9 million, or $1.20 per share, helped by a $38.0 million gain on a Sarepta litigation settlement; the company said its cash runway extends into late Q4 2027.
Key points
- Q3 2026 revenues were $9.2 million versus $29.7 million in Q3 2025; ZOLGENSMA royalty revenue fell $21.2 million.
- Net loss was $40.7 million, or $0.62 per share, versus $61.9 million, or $1.20 per share, a year earlier.
- Q3 included a $38.0 million gain on the Sarepta settlement; the $39.0 million payment was received in October 2026.
- Cash, cash equivalents and marketable securities were $251.0 million at September 30, 2026; the company expects this plus the settlement proceeds to fund operations into late Q4 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.